Literature DB >> 12022026

Massive vascular endothelium growth factor (VEGF) expression in Eales' disease.

Yannis Perentes1, Chi Chao Chan, Etienne Bovey, Sylvie Uffer, Carl P Herbort.   

Abstract

BACKGROUND: Eales' disease is an idiopathic retinal vasculitic and vaso-occlusive process complicated by extensive retinal neovascularisation and vitreous hemorrhages. The great propensity to produce retinal neovessels is one of the particular aspects of the disease that deserves to be further investigated. We report a case of Eales' disease having evolved over more than three decades, with a typical clinical presentation in one eye, while the other eye had to be enucleated because of a terminal neovascular glaucoma, thus allowing pathological examination.
METHODS: The functional right eye was treated by vitrectomy, cerclage, cryocoagulation and endolaser. The non-functional phthitic left eye was enucleated and submitted for histopathological and immunohistochemical examination using antibodies against vascular endothelial growth factor, T-cells, B-cells and Müller cells.
RESULTS: Evolution was favourable in the operated right eye, following management of the inflammatory reaction. The histopathological examination of the left eye revealed an occlusion of the anterior chamber angle by rubeosis iridis, tractional retinal detachments, pre-, intra- and sub-retinal neovascular membranes, and vitrous hemorrhages. Diffuse positive anti-VEGF immunostaining was found at the level of the retinal neovascular membranes. The retina exhibited prominent Müller cell immunostaining, indicating extensive gliosis, and predominantly B cell infiltrates were found in the eye.
CONCLUSION: The present study indicates a close relationship between the prominent neovascular proliferation in Eales' disease and the intense expression of VEGF. The increased expression of VEGF, when compared to other conditions inducing neovascularisation, might explain the severity of neovascular growth and the propensity of repeated vitrous hemorrhages in Eales' disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12022026     DOI: 10.1055/s-2002-30662

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  10 in total

1.  Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease.

Authors:  Atul Kumar; Sri Vatsa Sehra; M B Thirumalesh; Varun Gogia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-15       Impact factor: 3.117

Review 2.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

3.  Intravitreal bevacizumab to facilitate vitrectomy in idiopathic ischaemic retinal vasculitis.

Authors:  Roger Wong; Bhaskar Gupta; Miles R Stanford; D Alistair H Laidlaw
Journal:  Int Ophthalmol       Date:  2009-12-10       Impact factor: 2.031

4.  Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis.

Authors:  Salim Ben Yahia; Carl P Herbort; Salah Jenzeri; Kamel Hmidi; Sonia Attia; Riadh Messaoud; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2008-04-10       Impact factor: 2.031

5.  An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.

Authors:  Lei Feng; Jiang-Hua Hu; Jie Chen; Xin Xie
Journal:  J Zhejiang Univ Sci B       Date:  2018 Apr.       Impact factor: 3.066

6.  Intra-ocular expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) in a case of Eales' disease by immunohistochemical analysis: a case report.

Authors:  Aditya Verma; Jyotirmay Biswas; Selvi Radhakrishnan; Angayarkanni Narayanasamy
Journal:  Int Ophthalmol       Date:  2010-01-05       Impact factor: 2.031

7.  Inflammatory optic disc neovascularisation managed with oral steroids/immunosuppressants and intravitreal ranibizumab.

Authors:  Babu Lal Kumawat; Rohan Chawla; Pradeep Venkatesh; Koushik Tripathy
Journal:  BMJ Case Rep       Date:  2017-11-03

8.  Treatment of neuro-ophthalmologic manifestations of tuberculosis.

Authors:  Susannah Mistr; Pamela S Chavis
Journal:  Curr Treat Options Neurol       Date:  2006-01       Impact factor: 3.972

9.  Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.

Authors:  Ahmad M Mansour; Friederike Mackensen; Padmamalini Mahendradas; Moncef Khairallah; Timothy Yy Lai; Ziad Bashshur
Journal:  Clin Ophthalmol       Date:  2012-08-01

10.  Intravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots.

Authors:  Alfredo Pece; Davide Allegrini; Stelios Kontadakis; Giuseppe Querques; Luca Rossetti
Journal:  BMC Ophthalmol       Date:  2016-07-26       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.